On July 16, Skolkovo residents met Veronika Skvortsova, head of the Federal medical and biological agency (FMBA) of Russia. Six CEOs of biomedical companies presented their products to the head of the FMBA and discussed the prospects for implementing the developed solutions at the clinics of the Agency, conducting clinical trials as well as opportunities for contract development of solutions to meet the needs of the FMBA.
Dmitry Romashin, Development Director at Efferon, showcased a similarly-named device for extracorporeal blood purification. Veronika Skvortsova said that FMBA is willing to examine the possibility of conducting clinical trials for extracorporeal blood purification devices: "Given that toxicology and a large pool of hematology and transfusiology institutions are part of the FMBA of Russia, the proposed method may turn out to be very popular for a wide range of tasks. In particular, there is potential for using it in the treatment of COVID-19, but this naturally requires detailed research."
Veronika Skvortsova, head of the Federal medical and biological agency of Russia: "The Agency is represented by a wide network of institutions from different fields - ranging from basic science to high-tech applied medicine. By using this database and with the support of Skolkovo residents, we will be able to implement many projects conductive to develop domestic medicine."
In spring 2020, Nanolek and Efferon entered into a strategic partnership targeted at vigorous roll-out of sorption columns to market. The Efferon LPS and Efferon CT columns are currently successfully used in a number of clinics in Moscow, St. Petersburg, Rostov-on-Don, Nizhny Novgorod, Surgut and other cities across the Russian Federation in the treatment of sepsis, bacterial-viral pneumonia, acute respiratory distress syndrome (ARDS) and the cytokine storm.
